About Cornerstone Therapeutics
Cornerstone Therapeutics is a Healthcare company based in Cary (United States) founded in 2003, and was acquired by Chiesi Pharmaceuticals in February 2014. Pharmaceutical products for respiratory markets are developed and commercialized. The company has 318 employees. Cornerstone Therapeutics has completed 2 acquisitions, including Cardiokine and EKR Therapeutics. The company was acqui-hired. Its focus areas include Life Sciences, Pulmonology, Drugs and Diversified. Its competitors include aTyr Pharma, ReCode Therapeutics and GEn1E; 3 of its 3 listed competitors have raised funding.
Company details
Cornerstone acquired by Chiesi Farmaceutici SpA is a pharmaceutical firm with five marketed products. The products include ZYFLO, an orally ingested treatment for asthma, CARDENE (nicardipine), an injected treatment for hypertension, CUROSURF which is a lung surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in infants, PERTZE that is used to treat exocrine pancreatic insufficiency (EPI), BETHKIS another CF-related treatment (for Pseudomonas aeruginosa - PA) and generic version of Tussionex (an allergy treatment).
- Headquarters Cary, United States
- Employees 318
- Stage Acquired
- SectorsHealthcare
- Website crtx.com
- Social LinkedIn
- Acquired by Chiesi Pharmaceuticals (Feb 2014)
- Latest Funding Round$30M (USD), Debt – Conventional
Jul 2012
- Investors
- Employee Count318
- Investments & AcquisitionsCardiokine
& 1 more
- Acquired byChiesi Pharmaceuticals
(Feb 2014)
Funding Insights of Cornerstone Therapeutics
- Total Rounds 1
- Last Round Debt – Conventional — $30M
- First Round $30M
(Jul 2012)
All 1 funding rounds of Cornerstone Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2012 | $30M | Debt – Conventional | – | – | – |
1 investors in total: 1 institutional.
Investors in Cornerstone Therapeutics
Cornerstone Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Chiesi Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of drugs for respiratory, neonatology, rare disease and special care therapeutic areas | 1935 | chiesi.com | Parma, Italy |
Investor details for Cornerstone Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cornerstone Therapeutics
Cornerstone Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cardiokine and EKR Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Oncology supportive care and generic products are manufactured and commercialized. | ekrtx.com | Bedminster, United States | 2005 | May 2012 | $150M | |
Pharmaceuticals for cardiovascular disease prevention and treatment are developed. | cardiokine.com | Philadelphia, United States | 2003 | Jan 2012 | •••• |
Complete acquisition details for Cornerstone Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cornerstone Therapeutics
5 dated milestones of Cornerstone Therapeutics across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Cornerstone Therapeutics is founded.
- Acquisition Acquires Cardiokine.
- Acquisition Acquires EKR Therapeutics.
- Funding First funding round of $30.0M.
- Exit Acquired by Chiesi Pharmaceuticals.
Competitors of Cornerstone Therapeutics
Cornerstone Therapeutics has 3 listed competitors in our database, 3 of them funded. They include aTyr Pharma, ReCode Therapeutics and GEn1E.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| atyrpharma.com | 2005 | San Diego, United States | $171.52M | 65 | Protein biologics are developed for treating rare diseases. | |
| recodetx.com | 2015 | Menlo Park, United States | $371M | Precision medicines for lung-related diseases are developed. | ||
| gen1e.com | 2018 | Palo Alto, United States | $17.15M | Developer of therapeutics for the treatment of inflammatory and rare diseases |
Detailed competitors of Cornerstone Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pulmonology
3 companies that operate in the same segment as Cornerstone Therapeutics (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cornerstone Therapeutics
Cornerstone Therapeutics was founded in 2003 and raised its 1st funding round 9 years after it was founded.
Cornerstone Therapeutics is headquartered in Cary, United States. It is registered at Cary, North Carolina, United States.
Cornerstone Therapeutics has 318 employees.
Cornerstone acquired by Chiesi Farmaceutici SpA is a pharmaceutical firm with five marketed products. The products include ZYFLO, an orally ingested treatment for asthma, CARDENE (nicardipine), an injected treatment for hypertension, CUROSURF which is a lung surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in infants, PERTZE that is used to treat exocrine pancreatic insufficiency (EPI), BETHKIS another CF-related treatment (for Pseudomonas aeruginosa - PA) and generic version of Tussionex (an allergy treatment).
Cornerstone Therapeutics's top competitors include aTyr Pharma, ReCode Therapeutics and GEn1E.
Cornerstone Therapeutics has made 2 acquisitions, including Cardiokine, and EKR Therapeutics.
Cornerstone Therapeutics has 1 investor. Key investors include Chiesi Pharmaceuticals.
Yes. Cornerstone Therapeutics was acquired by Chiesi Pharmaceuticals in February 2014.